Literature DB >> 22634596

Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection.

Masayoshi Shinjoh1, Yaoko Takano, Takao Takahashi, Naoki Hasegawa, Satoshi Iwata, Norio Sugaya.   

Abstract

BACKGROUND: Postexposure prophylaxis (PEP) using neuraminidase inhibitors against exposure to influenza virus has been well studied in household settings but not in nosocomial settings in pediatric wards.
METHODS: We used oseltamivir or zanamivir as PEP in our pediatric wards. All influenza cases were diagnosed by the influenza rapid diagnostic test.
RESULTS: Between 2003 and 2011, there were 20 nosocomial introductions of influenza (10 were A, 9 were B and 1 was undetermined). The index cases consisted of 17 inpatients, 2 parents and 1 medical staff member. The 17 inpatients had been admitted to the hospital for reasons other than infectious disease and they developed influenza after hospitalization. Among the 81 contacts, 28 (35%) were exposed to influenza A, and 52 (64%) were exposed to influenza B. The rate of secondary infection among contacts not given PEP was 29% (5/17), and the rate among contacts given PEP was significantly lower, 3% (2/63; P = 0.004). The 2 infected contacts who had been given PEP were both influenza B cases, and both had received oseltamivir. The contacts who received PEP within 24 hours (59), for influenza A (23) and those who received zanamivir (15) did not develop influenza. No adverse events were reported.
CONCLUSIONS: PEP using oseltamivir or zanamivir for unexpected occurrences of nosocomial influenza in pediatric wards is safe and effective. The influenza rapid diagnostic test that we used was helpful for detecting nosocomial influenza in children.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634596     DOI: 10.1097/INF.0b013e318260265a

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 2.  Antivirals in the 2009 pandemic--lessons and implications for future strategies.

Authors:  Deeva Berera; Maria Zambon
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

3.  A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.

Authors:  Bindumadhav M Marathe; Heba H Mostafa; Peter Vogel; Philippe Noriel Q Pascua; Jeremy C Jones; Charles J Russell; Richard J Webby; Elena A Govorkova
Journal:  Antiviral Res       Date:  2017-10-31       Impact factor: 5.970

4.  Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.

Authors:  Nobuhisa Ishiguro; Yoichi M Ito; Sumio Iwasaki; Miki Nagao; Hideki Kawamura; Shinichiro Kanai; Yoko Nukui; Koichi Tokuda; Takayuki Miyara; Hidetoshi Igari; Koichi Yamada; Hiroki Chikumi; Chiaki Sano; Ryuji Koike; Tetsuya Yagi; Nobuo Murakami
Journal:  BMC Infect Dis       Date:  2021-08-30       Impact factor: 3.090

5.  Clinical impact of nosocomial infection with pandemic influenza A (H1N1) 2009 in a respiratory ward in Guangzhou.

Authors:  Yangqing Zhan; Xiaojuan Chen; Weijie Guan; Wenda Guan; Chunguang Yang; Sihua Pan; Sook-San Wong; Rongchang Chen; Feng Ye
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.